Zuellig Pharma
Concise Prescribing Info
Triptorelin acetate
Decapeptyl Down regulation & prevention of premature LH surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies. Pre-op reduction of myoma size to reduce the symptoms of bleeding & pain in women w/ symptomatic uterine myomas. Symptomatic endometriosis confirmed by laparoscopy when suppression of the ovarian homonogenesis is indicated to the extent that surgical therapy is not primarily indicated. Decapeptyl CR Situations where lowering of sex steroid serum levels to castrate levels is desired eg, prostate cancer, endometriosis, uterine myoma & assisted reproduction technique (ART). Confirmed central precocious puberty in girls <9 yr & boys <10 yr.
Dosage/Direction for Use
Decapeptyl Administer by SC inj daily into the lower abdominal wall. Down regulation & prevention of premature LH surges Start in day 2 or 3 of the menstrual cycle or day 21-23 of the menstrual cycle or 5-7 days before expected start of menses. Controlled ovarian hyperstimulation w/ gonadotropins should be started after 2-4 wk of treatment. Total duration: 4-7 wk. Uterine myomas & endometriosis Duration: Depends on initial degree of severity of endometriosis, & clinical manifestations & uterine myomas vol evolution. Max duration: 6 mth. Decapeptyl CR Depot inj Prostate cancer, endometriosis, uterine myoma One IM/SC inj once every 28 days. Female Max treatment period: 6 mth. Central precocious puberty Childn >30 kg 3.75 mg, 20-30 kg 2.5 mg, <20 kg 1.875 mg. Administer on day 0, 14 & 28. Then repeat the same dose every 4 wk. Dose may be repeated every 3 wk if insufficient effect. Stop treatment if bone maturation of >12 yr in girls & >13 yr in boys has been achieved. In vitro fertilisation (IVF) Depot inj Single administration on cycle day 2 or 3 (follicular phase) or cycle day 22 (luteal phase).
Hypersensitivity to triptorelin or gonadotrophin releasing hormone (GnRH) or any other GnRH analogue. Pregnancy & lactation. Severe osteoporosis. Decapeptyl CR Men: Hormone-independent prostate carcinoma. Following surgical castration. Women: Clinically manifest osteoporosis or risk of osteoporosis. Progressive brain tumours in childn. ART: Great precaution needed when number of detected follicles >10.
Special Precautions
Decapeptyl Renal or hepatic impairment. Concomitant use w/ drugs affecting pituitary secretion of gonadotrophins. Ovarian hyperstimulation syndrome; withhold hCG & advise patient to refrain from coitus or use barrier method for at least 4 days if OHSS occurs. Examine women of child-bearing potential carefully before treatment. Polycystic ovarian disease patients. Menstruation does not occur during treatment & will resume 7-12 wk after the final inj. Non-hormonal contraception should be used during initial mth of treatment, & from 4 wk after the last inj. Decreased bone density if used over several mth; treatment w/o add-back therapy should not exceed duration of 6 mth. Risk of osteoporosis. Decapeptyl CR Monitor sex steroid serum levels. Hormonal methods of contraception & prep containing estrogens should not be used during therapy. Childn: Chronological age at beginning of therapy should be <9 yr in girls & <10 yr in boys. Special forms of precocious puberty should be precluded.
Adverse Reactions
Decapeptyl Headache, abdominal pain, nausea, vag bleeding/spotting, inj site inflammation. Upper resp tract infection, pharyngitis; dizziness; hot flushes; vomiting, abdominal distension; back pain; abortion; pelvic pain, ovarian hyperstimulation syndrome, dysmenorrhoea, ovarian cysts; inj site pain/reaction, fatigue, influenza-like illness. Mood changes; bone pain; decreased libido, vag dryness; dyspaneunia; excessive perspiration. Decapeptyl CR In men: Hot flushes, impotence & loss of libido, rarely gynaecomastia. Depot inj causes depressive mood, increased enzyme activity & thrombophlebitis. In women: Hot flushes, bleeding or spotting, vag dryness &/or dyspareunia. Depot inj causes depressive mood, loss of libido, sporadically elevated enzyme levels, slight rise in serum cholesterol, paraesthesia, visual disturbances. Local reactions at inj site, mild allergic reaction, headache, fatigue & sleep disturbances. In childn: Occasional bleeding & discharge, vomiting, nausea & anaphylaxis.
ATC Classification
L02AE04 - triptorelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.
Decapeptyl inj 0.1 mg/mL
Decapeptyl CR inj 3.75 mg
(single-dose kit) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in